Q1 2026 Earnings Call February 25, 2026 8:00 AM ESTCompany ParticipantsChristine Viau - Head of Investor RelationsDarryl White ...
Johnson & Johnson's stock hits a 52-week high, but key drug patent risks and a lower Wall Street price target suggest downside. Learn more about JNJ stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results